Memorial Hospital Research Laboratories

The Nai-Kong Cheung Lab

Nai-Kong V. Cheung, MD, PhD

Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

Professor

My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

View Lab Overview

Featured News

Dr. Nai-Kong V. Cheung, Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology

At Work: Physician-Scientist Nai-Kong Cheung

Meet pediatric oncologist Nai-Kong Cheung, whose research into solid tumors is creating new hope for children with cancer.

Publications

Santich BH, Park JA, Tran H, Guo HF, Huse M, Cheung NV. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534). [reprint] [text]

Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Jun 15. pii: S1470-2045(18)30322-X. doi: 10.1016/S1470-2045(18)30322-X.

Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma – A Phase 1 Clinical Trial. JAMA Oncol. 2018 September 20. doi:10.1001/jamaoncol.2018.4005

Hoseini SS, Guo HF, Wu ZH, Hatano MN, Cheung NKV. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances 2(11):1250-1258, 2018

Wu ZH, Guo HF, Xu H, Cheung NKV. Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers. Mol Cancer Ther. 2018 Aug 6. pii: molcanther.0026.2018. doi: 10.1158/1535-7163.MCT-18-0026.

View All Publications

People

Nai-Kong V. Cheung, MD, PhD

Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

Professor

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
MD, PhD (Immunology), Harvard Medical School

[email protected]: Email Address
646-888-2313: Office Phone
View physician profile: Physician profile

Members

Irene Cheung, ScD — Irene Cheung
Laboratory Member and Attending Clinical Immunologist

Hong-fen Guo
Research Assistant/Specialist

Alan Long, PhD — Alan Long
Research Scholar

Jeong Park — Jeong A Park
Research Fellow

Mauricio Rendon-Bernot, MD — Mauricio Rendon-Bernot
Clinical Fellow

Yiwei Liu

Senior Research Scientist

Lab Alumni

Sayed Shahabuddin (Shahab) Hoseini
Research Associate

Tsung-Yi (Steven) Lin, PhD — Tsung-Yi (Steven) Lin
Research Fellow

Brian Santich — Brian H. Santich
Research Fellow

Linlin Wang , PhD — Linlin Wang
Research Associate

Mao (Sally) Wang, PhD — Mao (Sally) Wang
Research Fellow

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
646-888-2313

Office Phone
646-888-2320

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Nai-Kong V. Cheung discloses the following relationships and financial interests:

Abpro Inc
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Biotec Pharmacon
Intellectual Property Rights
Eureka Therapeutics Inc
Ownership / Equity Interests

Japanese Society of Hematology
Provision of Services (uncompensated)
National Institutes of Health (NIH)
Provision of Services
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures